

Pharmacologically Relevant Drug Interactions of Nitrovasodilators

Naina Mohamed Pakkir Maideen *

Pharmacologist, Dubai Health Authority, Dubai, United Arab Emirates

* **Corresponding Author:** Naina Mohamed Pakkir Maideen, Dubai Health Authority, PB No: 4545, Dubai, UAE. Tel: +97142164952, Email: nmmaideen@dha.gov.ae

Received November 22, 2019; Accepted December 20, 2019; Online Published January 01, 2020

Abstract

Nitrovasodilators are used to treat many conditions including coronary artery disease, chronic congestive heart failure, and arterial hypertension. They induce smooth muscle relaxation by increasing intracellular cyclic Guanosine Monophosphate (cGMP) concentrations and activating K⁺ channels through the release of Nitric Oxide (NO). Thus, they could interact with the drugs preventing the breakdown or increasing the synthesis of cGMP and induce the accumulation of cGMP resulting in excessive vasodilation and severe hypotension. Pharmacologically relevant drug interactions of Nitrovasodilators are discussed in this review.

Coadministration of Nitrovasodilators and the drugs preventing the breakdown of cGMP like Phosphodiesterase 5 (PDE5) inhibitors or the drugs increasing the synthesis of cGMP like Riociguat could induce the accumulation of cGMP resulting in excessive vasodilation and severe hypotension. The prescribers and pharmacists are required to be aware of the drugs interacting with Nitrates to predict and prevent the adverse drug interactions.

Keywords: Drug Interactions, Nitrovasodilators, Nitrates, Nitroglycerin.

Introduction

Nitrovasodilators are the agents useful in the management of conditions like coronary artery disease, chronic congestive heart failure, and arterial hypertension and they include short-acting sublingual Glyceryl Trinitrate (GTN) and long-acting nitrates such as Isosorbide Mononitrate (ISMN) and Isosorbide Dinitrate (ISDN) and other drugs like Sodium Nitroprusside and Nicorandil.¹ They release NO which activates soluble Guanylyl Cyclase (GC) of smooth muscle to form cGMP. Smooth muscle relaxation is achieved through increased intracellular cGMP that inhibits calcium entry into the cell, thereby decreasing intracellular calcium concentrations. Smooth muscle relaxation is also induced by NO, which activates K⁺ channels, leading to hyperpolarization and relaxation.²

Modification of the effects of one drug by concomitantly administered drugs, herbs or nutrients is termed “drug interaction” and the drug interaction resulting in increased adverse effects or decreased therapeutic efficacy is known as “adverse drug interaction”.^{3,4} The pharmacokinetics or pharmacodynamics profile of the drugs are altered by the interacting drug.⁵

Results and Discussion

Nitrovasodilators increase the plasma concentrations of cGMP by stimulating soluble GC enzyme and the drugs preventing the breakdown or increasing the synthesis of cGMP can induce the accumulation of cGMP resulting in

excessive vasodilation and severe hypotension. Hence, Nitrovasodilators could interact with PDE5 inhibitors and Riociguat.

Phosphodiesterase 5 (PDE5) Inhibitors

The Phosphodiesterase 5 (PDE5) inhibitors are recommended as first-line drugs to treat Erectile Dysfunction (ED) and they include Sildenafil, Tadalafil and Vardenafil.⁶ The predominant phosphodiesterase in the corpus cavernosum is PDE5 and its inhibition by PDE5 inhibitors prevent the breakdown of cGMP leading to increased concentration of cGMP resulting in relaxation of arterial and trabecular smooth muscle, leading to arterial dilatation, venous constriction, and erection.⁷

Marked vasodilation and severe hypotension could occur in patients receiving Nitrates, PDE5 inhibitors concomitantly, due to excessive accumulation of cGMP as the Nitrates increase the production of cGMP, and the PDE5 inhibitors prevent the breakdown of cGMP.⁸

Nitrates are not recommended to be administered within 24 hours of use of Sildenafil or 48 hours of use of Tadalafil.⁹ Hence, the patients can be administered with Nitrates after 24 hours of Sildenafil intake as it was suggested by the American College of Cardiology and American Heart Association.¹⁰ The patients on Nitrates are recommended to withhold their Nitrates at least for 48 hours, after the intake of Tadalafil. Also, the restarting of Nitrates should be done with monitoring.¹¹

Riociguat

Riociguat is a stimulator of the soluble Guanylate Cyclase (sGC) enzyme which is indicated in the treatment of pulmonary hypertension.¹² Riociguat increases the intracellular cGMP levels by stimulating sGC and sensitizing sGC to endogenous NO.¹³ Additive hypotensive effect is expected in patients receiving Nitrates and Riociguat concurrently, due to excessive accumulation of cGMP [14].

Alteplase

Alteplase is a recombinant tissue Plasminogen Activator (rtPA) which is used as a thrombolytic drug to treat acute ischemic stroke, pulmonary embolism and acute myocardial infarction.¹⁵ Concurrent use of Alteplase and Nitroglycerin (Glyceryl Trinitrate (GTN)) decreased the plasma concentration of Alteplase due to enhanced degradation of Alteplase in plasma while the thrombolytic activity of Alteplase has been decreased.^{16,17}

Heparin

Heparin is an anticoagulant drug which is used to treat conditions like Acute Coronary Syndrome (ACS), Atrial Fibrillation (AF), Deep-Vein Thrombosis (DVT), Pulmonary Embolism (PE) etc.¹⁸ Concomitant use of Nitroglycerin and Heparin resulted in an impaired anticoagulant activity of Heparin. Also, it is worth mentioning that the monitoring of the International Normalized Ratio (INR) is recommended when both drugs are used concurrently.¹⁹

Conclusion

The drugs preventing the breakdown or increasing the synthesis of cGMP could interact with Nitrovasodilators and induce the accumulation of cGMP resulting in excessive vasodilation and severe hypotension. The Phosphodiesterase 5 (PDE5) such as Sildenafil, Tadalafil and Vardenafil prevent the breakdown of cGMP while Riociguat increases the synthesis of cGMP. In addition, the thrombolytic activity of Alteplase and the anticoagulant activity of Heparin are affected by the coadministration of Nitroglycerin. The prescribers and pharmacists are required to be aware of the drugs interacting with Nitrates to predict and prevent the adverse drug interactions.

Conflicts of Interest

The author declared no potential conflict of interests with respect to the research, authorship, and/or publication of this article.

Funding

The author received no financial funding or support for the research.

References

1. Tarkin JM, Kaski JC. Vasodilator therapy: nitrates and nicorandil. *Cardiovascular drugs and therapy*. 2016;30(4):367-78. doi:10.1007/s10557-016-6668-z
2. Ignarro LJ, Ross G, Tillisch J. Pharmacology of endothelium-derived nitric oxide and nitrovasodilators. *Western Journal of Medicine*. 1991;154(1):51.
3. Maideen NMP. Thiazolidinediones and their Drug Interactions involving CYP enzymes. *A J Physiol Biochem Pharmacol*. 2018; 8(2): 47-54. doi: 10.5455/ajpbp.20181022083057
4. Maideen NM. Tobacco smoking and its drug interactions with comedications involving CYP and UGT enzymes and nicotine. *World Journal of Pharmacology*. 2019;8(2):14-25.
5. Pakkir Maideen NM, Manavalan G, Balasubramanian K. Drug interactions of meglitinide antidiabetics involving CYP enzymes and OATP1B1 transporter. *Therapeutic advances in endocrinology and metabolism*. 2018;9(8):259-68. doi: 10.1177/2042018818767220
6. Wright PJ. Comparison of phosphodiesterase type 5 (PDE5) inhibitors. *International journal of clinical practice*. 2006;60(8): 967-75. doi: 10.1111/j.1742-1241.2006.01049.x
7. Corbin JD. Mechanisms of action of PDE5 inhibition in erectile dysfunction. *International journal of impotence research*. 2004; 16 (S1): S4. doi: 10.4103/2230-8210.159023
8. Schwartz BG, Kloner RA. Drug interactions with phosphodiesterase-5 inhibitors used for the treatment of erectile dysfunction or pulmonary hypertension. *Circulation*. 2010 ;122 (1):88-95. doi: 10.1161/CIRCULATIONAHA.110.944603
9. Lazaro VL. 2014 PHA Clinical Practice Guidelines for the Diagnosis and Management of Patients with Coronary Heart Disease. *ASEAN Heart Journal: Official Journal of the ASEAN Federation of Cardiology*. 2016;24. doi: 10.7603/s40602-016-0003-6
10. Cheitlin MD, Hutter AM, Brindis RG, Ganz P, Kaul S, Russell RO, Zusman RM, Forrester JS, Douglas PS, Faxon DP, Fisher JD. Use of sildenafil (Viagra) in patients with cardiovascular disease. *Journal of the American College of Cardiology*. 1999;33(1):273-82.
11. Schwartz BG, Kloner RA. Drug interactions with phosphodiesterase-5 inhibitors used for the treatment of erectile dysfunction or pulmonary hypertension. *Circulation*. 2010 ;122 (1):88-95. doi: 10.1161/CIRCULATIONAHA.110.944603
12. Ghofrani HA, Humbert M, Langleben D, Schermuly R, Stasch JP, Wilkins MR, Klinger JR. Riociguat: mode of action and clinical development in pulmonary hypertension. *Chest*. 2017;151 (2):468-80. doi: 10.1016/j.chest.2016.05.024
13. Lian TY, Jiang X, Jing ZC. Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension. *Drug design, development and therapy*. 2017;11:1195. doi: 10.2147/DDDT.S117277
14. Khaybullina D, Patel A, Zerilli T. Riociguat (adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. *Pharmacy and Therapeutics*. 2014;39(11):749.
15. Gurman P, Miranda OR, Nathan A, Washington C, Rosen Y, Elman NM. Recombinant tissue plasminogen activators (rtPA): a review. *Clin Pharmacol Ther*. 2015;97(3):274-85. doi: 10.1002/cpt.33.
16. White CM, Fan C, Chen BP, Kluger J, Chow MS. Assessment of the drug interaction between alteplase and nitroglycerin: An in vitro study. *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy*. 2000;20(4):380-2. doi: 10.1592/phco.20.5.380.35057
17. Harder S, Klinkhardt U. Thrombolytics. *Drug safety*. 2000;23(5): 391-9. doi: 10.2165/00002018-200023050-00004
18. Reardon DP, Zemaitis C. Review of Anticoagulants. In: *Hemostasis in Dentistry 2018* (pp. 99-108). Springer, Cham.
19. Brack MJ, More RS, Hubner PJ, Gershlick AH. The effect of different nitrate preparations on plasma heparin concentrations and the activated partial thromboplastin time. *Postgraduate medical journal*. 1994;70(820):100-3. doi: 10.1136/pgmj.70.820.100